Close Menu

NEW YORK – CareDx reported after the close of the market on Thursday that its second quarter revenues rose 76 percent year over year, thanks largely to an 84 percent increase in testing services revenues.

For the three months ended June 30, the molecular diagnostics company reported total revenues of $31.5 million, up from $17.8 million during the same period a year earlier, and beating the average Wall Street estimate of $28.0 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.